<i>TP53</i>-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy

<i>TP53</i>-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy

Chimeric antigen receptor T (CAR T) cell immunotherapy has shown remarkable efficacy in non-Hodgkin’s lymphoma (NHL) patients. Minimal residual disease (MRD) monitoring in NHL is essential after CAR T cell therapy, which can be achieved by monitoring circulating tumor DNA (ctDNA). The mutation of &l...

Full description

Bibliographic Details
Main Authors: Liting Chen, Wei Mu, Jia Gu, Min Xiao, Liang Huang, Miao Zheng, Chunrui Li, Yi Xiao, Jianfeng Zhou, Xiaolu Long
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Diagnostics
Subjects:
non-Hodgkin’s lymphoma
chimeric antigen receptor T cell therapy
<i>TP53</i> mutation
circulating tumor DNA
droplet digital PCR
Online Access:https://www.mdpi.com/2075-4418/11/5/844

Internet

https://www.mdpi.com/2075-4418/11/5/844

Similar Items